Session N.00313


Thursday, 30 October 2014, 08:00 - 10:00

Room 112

Type
Symposium

Track
TB Bacteriology and Immunology

Topic
Vaccines / Drug development

Description
The current TB drug development pipeline holds a large number of new and existing TB drugs. Groups involved in the late stages of drug development include the TB Alliance; the commercial pharmaceutical, not-for-profit, and academic sectors; Panacea and EDCTP; Inter-TB at St. George’s Hospital; the TBTC and CDC; the HIV networks of NIAID and the trials of DMID, both at the U.S. NIH; the NIRT in Chennai, India; MSF; and the MRCs in United Kingdom and in South Africa. They seek to optimise existing drugs and develop novel compounds. This session presents emerging data from leading groups.

Target audience
TB clinicians and health care workers, TB programme managers, TB researchers, infectious disease clinicians, TB programme staff, epidemiologists and others involved in clinical trials, pharmacologists, drug developers.

Objectives
1. Present information on recent phase 2 & 3 trials of new TB drugs and regimens targeting drug-sensitive TB
2. Describe challenges confronting development of new TB therapies through presentation of practical experiences
3. Inform the target audience on safety of drugs
4. Assess the utility of new or imminently available TB drugs and regimens
5. Assess programmatic implications of emerging data from clinical trials

Keywords
Drug; treatment; clinical trial; regimen; therapy

Coordinator(s)
Andrew Vernon (USA), Gavin Churchyard (South Africa)

Chair(s)
William Mac Kenzie (USA), Christian Lienhardt (Switzerland)

Presentations
08:00 - 08:15 The role of fluoroquinolones in treatment of drug-sensitive TB: what have we learnt from recent phase 2 and phase 3 trials
Richard E Chaisson (USA)

08:20 - 08:35 High Dose Rifamycins: the promise of increased efficacy
Amina Jindani (UK), Martin Boeree (Netherlands)

08:40 - 08:55 High Dose Rifamycins: insights into kinetics, adverse effects and drug interactions
Kelly Dooley (USA), Rada Savic (USA)

09:00 - 09:15 The potential impact of 3-and 4-month regimens: insights from modelling
David W Dowdy (USA)

09:20 - 09:35 Rifamycins for latent TB: perspectives from settings of low-and high-incidence
Robert Belknap (USA), Neil Martinson (South Africa)

09:40 - 09:55 Clofazimine as an anti-tuberculosis drug
Jacques Grosset (USA)